Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
For full access to this article login to GEN Select now.
RNAi Brings Analytical Value to Pharma R&D
Corroborative Studies and New Data Analysis Approaches Overcome Pervasive Drawbacks
- In the decade since the discovery of siRNA, the use of these molecules as therapeutics has received ample R&D investment and delivered a lot of promise. In the past two and a half months alone, several companies have reported positive clinical trial results for RNAi drug candidates. The ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.